Phase 3 Trials Show Bepirovirsen Achieves Functional Cure for Hepatitis B in 20% of Patients
By
Diana Swift
Summary
Phase 3 trial results published in The New England Journal of Medicine show that bepirovirsen, a novel antisense oligonucleotide targeting hepatitis B virus transcripts, achieved a functional cure in approximately 20% of patients at 72 weeks after therapy discontinuation, compared to zero in placebo groups. The twin B-Well 1 and B-Well 2 trials demonstrated that 20% and 19% of treated patients respectively achieved functional cure, marking a significant milestone in hepatitis B treatment research.
Source
Twitter / XPhase 3 Trials Show Bepirovirsen Achieves Functional Cure for Hepatitis B in 20% of Patientsmdsc.peKey quotes
· 3 pulledOne in 5 patients on the drug achieved a functional cure at week 72 after therapy discontinuation compared with zero placebo patients
In the B-Well 1 trial, 127 of 650 patients (20%) vs zero of 328 patients
In the B-Well 2 trial, 106 of 570 patients (19%) vs zero of 286 patients
You might also wanna read
Gene therapy shows promise for functional HIV cure in monkey study
A gene-therapy study published in Science Translational Medicine shows promise for a 'functional cure' for HIV. Researchers delivered a gene
science.org·22d ago
Phase 1 trial finds triple monoclonal antibody combination safe and effective for HIV-1 prevention
This phase 1, multicentre, randomised, open-label trial (HVTN 140/HPTN 101 part B) evaluated the safety, pharmacokinetics, and neutralisatio
Lenacapavir and the shift to NRTI-free, long-acting HIV treatment: implications for HBV patients
The article discusses the evolving HIV treatment landscape, focusing on the shift toward NRTI-free dual regimens and long-acting injectable
https://doi.org/10.1056/NEJMoa2517384
https://doi.org/10.1001/jamaneurol.2026.1021
Comments
Sign in to join the conversation.
No comments yet. Be the first.